

## Quality Indicators for Colonoscopy and the Risk of Interval Cancer

Michał F. Kaminski, M.D., Jarosław Reguła, M.D., Ewa Kraszewska, M.Sc.,  
Marcin Polkowski, M.D., Urszula Wojciechowska, M.D., Joanna Didkowska, M.D.,  
Maria Zwierko, M.D., Maciej Rupinski, M.D., Marek P. Nowacki, M.D.,  
and Eugeniusz Butruk, M.D.

### ABSTRACT

Although rates of detection of adenomatous lesions (tumors or polyps) and cecal intubation are recommended for use as quality indicators for screening colonoscopy, these measurements have not been validated, and their importance remains uncertain.

We used a multivariate Cox proportional-hazards regression model to evaluate the influence of quality indicators for colonoscopy on the risk of interval cancer. Data were collected from 186 endoscopists who were involved in a colonoscopy-based colorectal-cancer screening program involving 45,026 subjects. Interval cancer was defined as colorectal adenocarcinoma that was diagnosed between the time of screening colonoscopy and the scheduled time of surveillance colonoscopy. We derived data on quality indicators for colonoscopy from the screening program's database and data on interval cancers from cancer registries. The primary aim of the study was to assess the association between quality indicators for colonoscopy and the risk of interval cancer.

A total of 42 interval colorectal cancers were identified during a period of 188,788 person-years. The endoscopist's rate of detection of adenomas was significantly associated with the risk of interval colorectal cancer ( $P=0.008$ ), whereas the rate of cecal intubation was not significantly associated with this risk ( $P=0.50$ ). The hazard ratios for adenoma detection rates of less than 11.0%, 11.0 to 14.9%, and 15.0 to 19.9%, as compared with a rate of 20.0% or higher, were 10.94 (95% confidence interval [CI], 1.37 to 87.01), 10.75 (95% CI, 1.36 to 85.06), and 12.50 (95% CI, 1.51 to 103.43), respectively ( $P=0.02$  for all comparisons).

The adenoma detection rate is an independent predictor of the risk of interval colorectal cancer after screening colonoscopy.

From the Department of Gastroenterology (M.F.K., J.R., M.P., M.R., E.B.), the National Cancer Registry of Poland (U.W., J.D.), the Masovian Cancer Registry (M.Z.), and the Department of Colorectal Cancer (M.P.N.), Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; and the Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education (J.R., E.K., M.P., M.R., E.B.) — both in Warsaw, Poland. Address reprint requests to Dr. Reguła at the Department of Gastroenterology, Institute of Oncology, Roentgen St. 5, Warsaw, Poland, or at [jregula@coi.waw.pl](mailto:jregula@coi.waw.pl).

N Engl J Med 2010;362:1795-803.  
Copyright © 2010 Massachusetts Medical Society.